Assertio Therapeutics (ASRT) Reports In-Line Q3 EPS; Raises Outlook
Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.24, in-line with the analyst estimate of $0.24. Revenue for the quarter ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)